Research programme: neonatal barrier therapeutics - CeragenixAlternative Names: NeoCeram
Latest Information Update: 07 May 2010
At a glance
- Originator Ceragenix Pharmaceuticals
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Suspended Skin disorders
Most Recent Events
- 07 May 2010 Suspended - Preclinical for Skin disorders in USA (Topical)
- 22 May 2008 Preclinical trials in Skin disorders in USA (Topical)